Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 76, Issue 5, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2016-210233
Keywords
-
Categories
Funding
- Ghent University
- fund of Scientific Research-Flanders (FWO)
- Research Council of Ghent University
- Interuniversity Attraction Pole (IUAP) grant Devrepair from the Belspo Agency [P7/07]
Ask authors/readers for more resources
Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to alpha 4 beta 7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the alpha 4 beta 7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of alpha 4 beta 7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available